Valérie Touitou

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski et al. · European Journal of Cancer · 2019 · 318 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Management and outcome of primary CNS lymphoma in the modern era

Caroline Houillier, Carole Soussain, Hervé Ghesquières et al. · Neurology · 2020 · 245 citations · Full text

Medicine, Oncology, Chemotherapy +12

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

H. Ghesquières, Marion Chevrier, Mouna Laadhari et al. · Annals of Oncology · 2019 · 237 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

High doses of biotin in chronic progressive multiple sclerosis: A pilot study

Frédéric Sedel, Caroline Papeix, Agnès Bellanger et al. · Multiple Sclerosis and Related Disorders · 2015 · 224 citations · Full text

Life Sciences, Neurology, Neuroscience +14

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial

Antonio Omuro, Olivier Chinot, Luc Taillandier et al. · The Lancet Haematology · 2015 · 205 citations

Medicine, Oncology, Pharmacotherapy +10